People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...
People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
6don MSN
Minimally invasive procedure for aortic valve disease has similar outcomes as surgery, study reports
People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...
PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and ...
GlobalData on MSN
Edwards solidifies TAVR dominance in long-term trial readout
The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.
Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...
Anteris Technologies (Nasdaq:AVR) today announced one-year clinical outcomes for its DurAVR transcatheter heart valve (THV).
Anteris Technologies has won FDA approval to conduct a key clinical trial for its heart valve device in the US.
Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback